Repligen (NASDAQ: RGEN) delivered a solid fourth-quarter and full-year 2019 earnings report yesterday. A combination of new product launches, continued contributions from past acquisitions, and growing demand for bioprocess products drove significant increases in nearly every financial metric. The company also reported that gene therapy customers were responsible for 15% of total revenue in 2019 and remain one of the best sources of growth.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,